In conclusion, the results presented in this study validate LGALS3BP as a suitable target for ADC therapy and provides a rationale for further clinical development of an anti-LGALS3BP based ADC for the treatment of neuroblastomas. Here, LGALS3BP is linked to neuroblastoma.